Cargando…

Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence

Therapeutic antibodies are an important tool in the arsenal against coronavirus infection. However, most antibodies developed early in the pandemic have lost most or all efficacy against newly emergent strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly those of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hastie, Kathryn M., Yu, Xiaoying, Ana-Sosa-Batiz, Fernanda, Zyla, Dawid S., Harkins, Stephanie S., Hariharan, Chitra, Wasserman, Hal, Zandonatti, Michelle A., Miller, Robyn, Maule, Erin, Kim, Kenneth, Valentine, Kristen M., Shresta, Sujan, Saphire, Erica Ollmann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083196/ https://www.ncbi.nlm.nih.gov/pubmed/37083327 http://dx.doi.org/10.1016/j.celrep.2023.112421

Ejemplares similares

SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model
por: Alves, Rubens Prince dos Santos, et al.
Publicado: (2023)

Structural Basis for the dsRNA Specificity of the Lassa Virus NP Exonuclease
por: Hastie, Kathryn M., et al.
Publicado: (2012)

Neutralizing Antibodies against Lassa Virus Lineage I
por: Buck, Tierra K., et al.
Publicado: (2022)

Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies
por: Enriquez, Adrian S., et al.
Publicado: (2022)

Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody
por: Callaway, Heather M., et al.
Publicado: (2022)

Lassa virus glycoprotein: stopping a moving target
por: Hastie, Kathryn M, et al.
Publicado: (2018)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
por: Nutalai, Rungtiwa, et al.
Publicado: (2022)

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
por: Wang, Yingdan, et al.
Publicado: (2022)

Neutralization susceptibility of Omicron lineages
por: Minton, Kirsty
Publicado: (2022)

Development and Structural Analysis of Antibody Therapeutics for Filoviruses
por: Yu, Xiaoying, et al.
Publicado: (2022)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
por: Chen, Zhaochun, et al.
Publicado: (2022)

Nanoparticle-based multivalent human antibodies offer potent and broad neutralization against Omicron sublineages
por: Wang, Yizhen, et al.
Publicado: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV
por: Hastie, Kathryn M., et al.
Publicado: (2016)

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
por: Zou, Jing, et al.
Publicado: (2022)

The Omicron Spectrometer
por: Allardyce, B W
Publicado: (1975)

The Omicron magnet
Publicado: (1977)

At the Omicron magnet
por: CERN PhotoLab
Publicado: (1977)

Understanding omicron
por: Le Page, Michael
Publicado: (2022)

Omicron emerges
por: Vaughan, Adam
Publicado: (2021)

Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2
por: Wang, Ying-Ting, et al.
Publicado: (2020)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses
por: Hastie, Kathryn M, et al.
Publicado: (2012)

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody
por: Yin, Wanchao, et al.
Publicado: (2022)

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
por: Chen, Chuan, et al.
Publicado: (2022)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
por: Wang, Xue-Jun, et al.
Publicado: (2022)

The emergence of the Omicron variant
por: Toovey, Oliver T.R., et al.
Publicado: (2022)

Another flavour of omicron
por: Le Page, Michael
Publicado: (2022)

An early look at Omicron
por: Vogel, Lauren
Publicado: (2022)

Omicron entry route
por: Pia, Luisanna, et al.
Publicado: (2022)

Omicron still on the rise
por: Wilson, Clare
Publicado: (2022)

Boosting in the age of Omicron
por: Sigal, Alex
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues
por: Yi, Chunyan, et al.
Publicado: (2022)

A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants
por: Modhiran, Naphak, et al.
Publicado: (2023)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection
por: Lee, Wen Shi, et al.
Publicado: (2023)

Post-Vaccination Neutralization Responses to Omicron Sub-Variants
por: Jacobsen, Henning, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6ftdlmmi1e26thb069qjpst88i